open access

Vol 76, No 1 (2017)
ORIGINAL ARTICLES
Published online: 2016-08-24
Submitted: 2016-04-07
Accepted: 2016-05-19
Get Citation

Inhibition of inducible nitric oxide synthase (iNOS) by simvastatin attenuates cardiac hypertrophy in rats

A. M. Ahmed
DOI: 10.5603/FM.a2016.0043
·
Pubmed: 27665951
·
Folia Morphol 2017;76(1):15-27.

open access

Vol 76, No 1 (2017)
ORIGINAL ARTICLES
Published online: 2016-08-24
Submitted: 2016-04-07
Accepted: 2016-05-19

Abstract

Background:The left ventricular hypertrophy (LVH) occurs in response to the haemodynamic overload in some physiological and pathological conditions. This study was designed to investigate the possible cardioprotective effect of simvastatin (SIM) treatment against isoproterenol (ISO)-induced LVH and the probable underlying mechanism in adult male Wistar rats.

Materials and methods: Animals were allocated into four groups. Rats of control group received normal saline orally for 30 days and intraperitoneally for the last 7 days. Rats of SIM group received SIM orally (10 mg/kg/day in saline) for 30 days. Rats of ISO group received normal saline orally for 30 days and ISO intraperitoneally (5 mg/kg) for the last 7 days to induce LVH. Rats of ISO/SIM group received SIM for 30 days and ISO intraperitoneally for the last 7 days. At the end of the experiment, all animals were sacrificed by cervical decapitation under anaesthesia. Truncal blood was collected and serum was separated and used for biochemical assay. The heart was dissected and processed for histological and immunohistochemical studies.

Results: The results of the present study confirmed the ISO-induced myocardial lesions including significant increase of heart weight (HW), heart weight/body weight (HW/BW) ratio, LVH, interstitial myocardial fibrosis (increased collagen types I and III), inflammatory cellular infiltration, necrosis of cardiomyocytes, and increased expression of inducible nitric oxide synthase (iNOS) and thioredoxin in cardiomyocytes. These changes were accompanied by significant increase in serum levels of troponin-T, creatine phosphokinase-MB (CPK-MB), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Co-administration of SIM to ISO-injected rats significantly reduced all these cardiac changes and serum biochemical markers in addition to marked depletion of iNOS and thioredoxin expression in cardiomyocytes.

Conclusions: It is concluded that SIM co-administration attenuated ISO-induced cardiac lesions including LVH by inhibiting iNOS expression in cardiomyocytes.  

Abstract

Background:The left ventricular hypertrophy (LVH) occurs in response to the haemodynamic overload in some physiological and pathological conditions. This study was designed to investigate the possible cardioprotective effect of simvastatin (SIM) treatment against isoproterenol (ISO)-induced LVH and the probable underlying mechanism in adult male Wistar rats.

Materials and methods: Animals were allocated into four groups. Rats of control group received normal saline orally for 30 days and intraperitoneally for the last 7 days. Rats of SIM group received SIM orally (10 mg/kg/day in saline) for 30 days. Rats of ISO group received normal saline orally for 30 days and ISO intraperitoneally (5 mg/kg) for the last 7 days to induce LVH. Rats of ISO/SIM group received SIM for 30 days and ISO intraperitoneally for the last 7 days. At the end of the experiment, all animals were sacrificed by cervical decapitation under anaesthesia. Truncal blood was collected and serum was separated and used for biochemical assay. The heart was dissected and processed for histological and immunohistochemical studies.

Results: The results of the present study confirmed the ISO-induced myocardial lesions including significant increase of heart weight (HW), heart weight/body weight (HW/BW) ratio, LVH, interstitial myocardial fibrosis (increased collagen types I and III), inflammatory cellular infiltration, necrosis of cardiomyocytes, and increased expression of inducible nitric oxide synthase (iNOS) and thioredoxin in cardiomyocytes. These changes were accompanied by significant increase in serum levels of troponin-T, creatine phosphokinase-MB (CPK-MB), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Co-administration of SIM to ISO-injected rats significantly reduced all these cardiac changes and serum biochemical markers in addition to marked depletion of iNOS and thioredoxin expression in cardiomyocytes.

Conclusions: It is concluded that SIM co-administration attenuated ISO-induced cardiac lesions including LVH by inhibiting iNOS expression in cardiomyocytes.  

Get Citation

Keywords

left ventricular hypertrophy, isoproterenol, simvastatin, inducible nitric oxide synthase, thioredoxin, collagen, rats, immunohistochemistry

About this article
Title

Inhibition of inducible nitric oxide synthase (iNOS) by simvastatin attenuates cardiac hypertrophy in rats

Journal

Folia Morphologica

Issue

Vol 76, No 1 (2017)

Pages

15-27

Published online

2016-08-24

DOI

10.5603/FM.a2016.0043

Pubmed

27665951

Bibliographic record

Folia Morphol 2017;76(1):15-27.

Keywords

left ventricular hypertrophy
isoproterenol
simvastatin
inducible nitric oxide synthase
thioredoxin
collagen
rats
immunohistochemistry

Authors

A. M. Ahmed

References (61)
  1. Abrahams C, Janicki JS, Weber KT. Myocardial hypertrophy in Macaca fascicularis. Structural remodeling of the collagen matrix. Lab Invest. 1987; 56(6): 676–683.
  2. Arnér ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000; 267(20): 6102–6109.
  3. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271(5 Pt 1): C1424–C1437.
  4. Benjamin IJ, Jalil JE, Tan LB, et al. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res. 1989; 65(3): 657–670.
  5. Boluyt MO, Long X, Eschenhagen T, et al. Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am J Physiol. 1995; 269(2 Pt 2): H638–H647.
  6. Bradbury P, Rae K. Connective tissues and stains. In: Bancroft J, Stevens A, editors. Theory and Practice of Histological Techqniues. 4th ed. Churchill Livingstone, London, New York, Toronto. 1999: pp. 113–138.
  7. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates. Comp Med. 2009; 59(4): 339–343.
  8. Chen YQ, Zhao LY, Zhang WZ, et al. Simvastatin reverses cardiomyocyte hypertrophy via the upregulation of phosphatase and tensin homolog expression. Exp Ther Med. 2015; 10(2): 797–803.
  9. Choudhary R, Mishra KP, Subramanyam C. Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant. Indian J Clin Biochem. 2006; 21(2): 107–113.
  10. Csont T, Viappiani S, Sawicka J, et al. The involvement of superoxide and iNOS-derived NO in cardiac dysfunction induced by pro-inflammatory cytokines. J Mol Cell Cardiol. 2005; 39(5): 833–840.
  11. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc. Med. 2002; 12(3): 97–101.
  12. Doering CW, Jalil JE, Janicki JS, et al. Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res. 1988; 22(10): 686–695.
  13. Escames G, Khaldy H, León J, et al. Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. J Hypertens. 2004; 22(3): 629–635.
  14. Ferdinandy P, Danial H, Ambrus I, et al. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res. 2000; 87(3): 241–247.
  15. Gealekman O, Abassi Z, Rubinstein I, et al. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation. 2002; 105(2): 236–243.
  16. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006; 48(5): 326–341.
  17. Guzy PM. Creatine phosphokinase-MB (CPK-MB) and the diagnosis of myocardial infarction. West J Med. 1977; 127(6): 455–460.
  18. Habib FM, Springall DR, Davies GJ, et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet. 1996; 347(9009): 1151–1155.
  19. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996; 93(6): 1087–1094.
  20. Henderson BC, Tyagi N, Ovechkin A, et al. Oxidative remodeling in pressure overload induced chronic heart failure. Eur J Heart Fail. 2007; 9(5): 450–457.
  21. Huang XY, Chen CX, Zhang XM, et al. Effects of ethanolic extract from Radix Scrophulariae on ventricular remodeling in rats. Phytomedicine. 2012; 19(3-4): 193–205.
  22. Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation. 2002; 106(16): 2118–2124.
  23. Jaeschke H. Mechanisms of oxidant stress-induced acute tissue injury. Proc Soc Exp Biol Med. 1995; 209(2): 104–111.
  24. Jalil JE, Doering CW, Janicki JS, et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 1989; 64(6): 1041–1050.
  25. Kaden J. IL-6 determination in serum of kidney graft recipients by a new bedside test: its diagnostic relevance. Transplant Proc. 2007; 39(2): 511–513.
  26. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008; 4(2): 341–353.
  27. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ. Res. 1996; 79(3): 363–380.
  28. Leenen FH. Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol. 1999; 15 Suppl A: 2A–7A.
  29. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med. 2000; 109(4): 315–323.
  30. Lin Y, Wang LN, Xi YH, et al. L-arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways. Basic Clin Pharmacol Toxicol. 2008; 103(2): 124–130.
  31. Liu YH, Carretero OA, Cingolani OH, et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol. 2005; 289(6): H2616–H2623.
  32. Lloyd-Jones DM, Larson MG, Leip EP, et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002; 106(24): 3068–3072.
  33. Martín-Fernández B, de las Heras N, Miana M, et al. Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. Exp Physiol. 2012; 97(6): 710–718.
  34. Masson S, Arosio B, Luvarà G, et al. Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J Mol Cell Cardiol. 1998; 30(8): 1505–1514.
  35. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007; 6(8): 617–635.
  36. Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest. 2002; 109(6): 735–743.
  37. Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation. 2000; 101(20): 2338–2341.
  38. Nadruz W, Lagosta VJ, Moreno H, et al. Simvastatin prevents load-induced protein tyrosine nitration in overloaded hearts. Hypertension. 2004; 43(5): 1060–1066.
  39. Narang D, Sood S, Thomas M, et al. Dietary palm olein oil augments cardiac antioxidant enzymes and protects against isoproterenol-induced myocardial necrosis in rats. J Pharm Pharmacol. 2005; 57(11): 1445–1451.
  40. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009; 123(2): 255–278.
  41. Querejeta R, López B, González A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004; 110(10): 1263–1268.
  42. RONA G, CHAPPEL CI, BALAZS T, et al. An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch Pathol. 1959; 67(4): 443–455.
  43. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985; 17(4): 291–306.
  44. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther. 2000; 86(1): 49–86.
  45. Shizukuda Y, Buttrick PM, Geenen DL, et al. beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol. 1998; 275(3 Pt 2): H961–H968.
  46. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001; 280(1): C53–C60.
  47. Song W, Lu X, Feng Q. Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res. 2000; 45(3): 595–602.
  48. Stevens A, Wilson I. The haematoxylins and eosin. In: Bancroft J, editors. Theory and Practice of Histological Techqniues. 4th ed. Churchill Livingstone, London, New York, Toronto. 1999: pp. 99–112.
  49. Sun Y, Carretero OA, Xu J, et al. Lack of inducible NO synthase reduces oxidative stress and enhances cardiac response to isoproterenol in mice with deoxycorticosterone acetate-salt hypertension. Hypertension. 2005; 46(6): 1355–1361.
  50. Swan HJ. Left ventricular dysfunction in ischemic heart disease: fundamental importance of the fibrous matrix. Cardiovasc Drugs Ther. 1994; 8 Suppl 2: 305–312.
  51. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001; 108(10): 1429–1437.
  52. Taylor PB, Tang Q. Development of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol. 1984; 62(4): 384–389.
  53. Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res. 1994; 75(1): 105–113.
  54. Torres SH, De Sanctis JB, de L Briceño M, et al. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol. 2004; 181(3): 419–427.
  55. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004; 44(3): 248–252.
  56. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996; 156(16): 1789–1796.
  57. Wan LH, Chen J, Li L, et al. Protective effects of Carthamus tinctorius injection on isoprenaline-induced myocardial injury in rats. Pharm Biol. 2011; 49(11): 1204–1209.
  58. Warren CM, Jordan MC, Roos KP, et al. Titin isoform expression in normal and hypertensive myocardium. Cardiovasc Res. 2003; 59(1): 86–94.
  59. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA. 1997; 94(13): 6954–6958.
  60. Yang J, Wang HX, Zhang YJ, et al. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy. J Ethnopharmacol. 2013 [Epub ahead of print].
  61. Zhang P, Xu X, Hu X, et al. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res. 2007; 100(7): 1089–1098.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl